{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:28:52Z","timestamp":1793964532554,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":169,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinsp.2026.101027","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:37:06Z","timestamp":1784356626000},"page":"101027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world 12-month outcomes of Risdiplam in spinal muscular atrophy types 2 and 3: A Brazilian cohort"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-8027","authenticated-orcid":false,"given":"Clara Gontijo","family":"Camelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-3353","authenticated-orcid":false,"given":"Rodrigo Holanda","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6359","authenticated-orcid":false,"given":"Cristiane Araujo Martins","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-8509","authenticated-orcid":false,"given":"Graziela Jorge","family":"Polido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-6336","authenticated-orcid":false,"given":"Eduardo Vital de","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7962-9636","authenticated-orcid":false,"given":"Weverton Carlos da Silva","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4962-3270","authenticated-orcid":false,"given":"Daniel Shoji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3112-216X","authenticated-orcid":false,"given":"Joemir Jabson da Concei\u00e7\u00e3o","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-0279","authenticated-orcid":false,"given":"Ciro","family":"Matsui Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-6760","authenticated-orcid":false,"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"9630","key":"10.1016\/j.clinsp.2026.101027_bib0002","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinsp.2026.101027_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101027_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clinsp.2026.101027_bib0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1016\/j.clinsp.2026.101027_bib0006","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101027_bib0007","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101027_bib0008","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-world data from Nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience","volume":"8","author":"Mendonca","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0011","first-page":"1","article-title":"Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy","volume":"82","author":"Zanoteli","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"issue":"10","key":"10.1016\/j.clinsp.2026.101027_bib0012","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101027_bib0013","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101027_bib0014","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment","volume":"30","author":"Mercuri","year":"2023","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101027_bib0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101027_bib0016","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3390\/jcm14093173","article-title":"Post-marketing safety of spinal muscular atrophy therapies: analysis of spontaneous adverse drug reactions from EudraVigilance","volume":"14","author":"Belancic","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0017","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","article-title":"Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany","volume":"17","author":"Hahn","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101027_bib0018","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1055\/s-0043-1772832","article-title":"Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation","volume":"81","author":"Alves","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101027_bib0019","first-page":"1","article-title":"Brazilian version of the Hammersmith Functional Motor Scale Expanded: cross-cultural adaptation and validation","volume":"82","author":"Moura","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101027_bib0020","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/cpt.2247","article-title":"Prognostic factors and treatment-effect modifiers in spinal muscular atrophy","volume":"110","author":"Baranello","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.clinsp.2026.101027_bib0021","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinsp.2026.101027_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-024-00456-y","article-title":"Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort","author":"Mendonca","year":"2024","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.clinsp.2026.101027_bib0023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101027_bib0024","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":"Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year","volume":"68","author":"Kaufmann","year":"2011","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101027_bib0025","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","article-title":"Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study","volume":"96","author":"Trucco","year":"2021","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.clinsp.2026.101027_bib0026","doi-asserted-by":"crossref","first-page":"e2103","DOI":"10.1212\/WNL.0000000000207878","article-title":"Systematic Literature Review of the natural history of spinal muscular atrophy: motor function, scoliosis, and contractures","volume":"101","author":"Aponte Ribero","year":"2023","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101027_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16517","article-title":"Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded","volume":"31","author":"Coratti","year":"2024","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0028","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101027_bib0029","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00415-023-11658-6","article-title":"Correction to: two\u2011year efficacy and safety of risdiplam in patients with type 2 or non\u2011ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101027_bib0030","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1097\/BPO.0000000000002759","article-title":"Scoliosis development in spinal muscular atrophy: the influences of genetic severity, functional level, and disease-modifying treatments","volume":"44","author":"Ciftci","year":"2024","journal-title":"J Pediatr Orthop"},{"issue":"11\u201312","key":"10.1016\/j.clinsp.2026.101027_bib0031","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.nmd.2022.11.004","article-title":"Long term follow-up of scoliosis progression in type II SMA patients","volume":"32","author":"Coratti","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.clinsp.2026.101027_bib0032","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s10072-025-08155-1","article-title":"Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review","volume":"46","author":"Gnazzo","year":"2025","journal-title":"Neurol Sci"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101027_bib0033","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.3390\/jcm13123467","article-title":"Spinal muscular atrophy scoliosis in the era of background therapies: a review of the literature","volume":"13","author":"Ruythooren","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinsp.2026.101027_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1226969","article-title":"Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era","volume":"14","author":"Giorgia","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.clinsp.2026.101027_bib0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening - opportunity or burden?","volume":"7","author":"Muller-Felber","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101027_bib0036","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1261\/rna.28106","article-title":"Off-target effects by siRNA can induce toxic phenotype","volume":"12","author":"Fedorov","year":"2006","journal-title":"RNA"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101027_bib0037","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41467-024-46090-5","article-title":"Specificity, synergy, and mechanisms of splice-modifying drugs","volume":"15","author":"Ishigami","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101027_bib0038","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.clinsp.2026.101027_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298609","article-title":"Exploration of adverse events associated with risdiplam use: retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yu","year":"2024","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101027_bib0040","first-page":"1","article-title":"A self-reported Brazilian registry of 5q-spinal muscular atrophy: data on natural history, genetic characteristics, and multidisciplinary care","volume":"82","author":"Mendonca","year":"2024","journal-title":"Arq Neuropsiquiatr"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226001559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226001559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:14:30Z","timestamp":1793963670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593226001559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S1807593226001559"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101027","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world 12-month outcomes of Risdiplam in spinal muscular atrophy types 2 and 3: A Brazilian cohort","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101027"}}